

AdnaGen® Announces Appointment of Chief Executive Officer

Langenhagen, Germany, April 10, 2008 – AdnaGen, a German company - of which 85% are owned by OncoVista Innovative Therapies Inc. (OTC BB: OVIT.OB) - engaged in the development and commercialization of proprietary diagnostics for the detection and molecular analysis of circulating tumor cells, announced the appointment of Dr. Wolfram Rodatz as Chief Executive Officer of AdnaGen, effective April 1, 2008.

AdnaGen's Managing Director, Dr. Winfried Albert, commented: "We are very glad for having now Dr. Rodatz on board whose vast experience in marketing and sales of life sciences and diagnostics products will be certainly a tremendous asset to reaching AdnaGen's goal to become a leader in the field."

OncoVista's Chief Executive Officer, Alexander L. Weis, Ph.D., stated: "We are very excited to have someone with Dr. Rodatz's tremendous expertise in the diagnostics field." Dr. Weis added, "Dr. Rodatz will be of great value in successfully managing and marketing AdnaGen's innovative and unique tumor diagnostic products and his leadership in this area will be instrumental in accelerating corporate growth at OncoVista."

Dr. Wolfram Rodatz stated: "I am very pleased to be joining AdnaGen's management team. The Company's approach to analyse biomarkers in circulating tumor cells is outstanding and I am looking forward to the challenge of expanding the market for this valuable technology."

Prior to joining AdnaGen, Dr. Rodatz was General Manager of Digilab BioVisioN GmbH, a German company offering technologies for peptide and protein marker discovery as well as sample preparation services and products. Before that, he was Managing Director Germany and General Manager Europe (including countries of the former Eastern bloc) at Bio-Rad Laboratories (AMEX: BIO), where he was key to building their life sciences and diagnostics business to annual revenues of over 100 Million Euros.

About AdnaGen AG

AdnaGen, founded in 1999, is a privately held biotechnology research and development company based in Langenhagen, Germany. AdnaGen focuses on the development of innovative tumor diagnostics by utilizing its proprietary technology for the detection and molecular analysis of rare but clinically important cells. Kits for breast and colon cancer are CE-marked and currently marketed in Europe. AdnaGen is ISO 9001 and EN 13485 certified. For more information, go to www.adnagen.com.

About OncoVista, Inc.

OncoVista, based in San Antonio, TX, is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies both through the acquisition of rights to technologies and drugs from others and through the development of proprietary products. OncoVista intends to identify, develop and rapidly commercialize innovative therapies for safer and more efficacious treatment of cancer. OncoVista's primary therapeutic strategy is based on targeting the patient's tumor(s) with treatments that will deliver drugs selectively based upon

specific biochemical characteristics of the cancer cells comprising the tumor. The company is utilizing the AdnaGen technology to drive its efforts to develop and bring to market more effective and less toxic drugs for treatment of cancer. For more information, go to www.oncovista.com.

Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. Prospective investors should be aware that these statements reflect only the judgements and projections of AdnaGen's and OncoVista's management, and no undue reliance should be placed on such forward looking statements.